133 related articles for article (PubMed ID: 23640062)
1. Prognostic impact of LDH levels in patients with relapsed/refractory seminoma.
Powles T; Bascoul-Mollevi C; Kramar A; Lorch A; Beyer J
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1311-6. PubMed ID: 23640062
[TBL] [Abstract][Full Text] [Related]
2. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
Beyer J; Collette L; Sauvé N; Daugaard G; Feldman DR; Tandstad T; Tryakin A; Stahl O; Gonzalez-Billalabeitia E; De Giorgi U; Culine S; de Wit R; Hansen AR; Bebek M; Terbuch A; Albany C; Hentrich M; Gietema JA; Negaard H; Huddart RA; Lorch A; Cafferty FH; Heng DYC; Sweeney CJ; Winquist E; Chovanec M; Fankhauser C; Stark D; Grimison P; Necchi A; Tran B; Heidenreich A; Shamash J; Sternberg CN; Vaughn DJ; Duran I; Bokemeyer C; Patrikidou A; Cathomas R; Assele S; Gillessen S;
J Clin Oncol; 2021 May; 39(14):1553-1562. PubMed ID: 33729863
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser CD; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Raggi D; Aurilio G; Casadei C; Hentrich M; Tran B; Dieckmann KP; Brito M; Ruf C; Mazzocca A; Vincenzi B; Stahl O; Bokemeyer C; Oing C
World J Urol; 2021 Sep; 39(9):3407-3414. PubMed ID: 33683412
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy.
Fosså SD; Oliver RT; Stenning SP; Horwich A; Wilkinson P; Read G; Mead GM; Roberts JT; Rustin G; Cullen MH; Kaye SB; Harland SJ; Cook P
Eur J Cancer; 1997 Aug; 33(9):1380-7. PubMed ID: 9337678
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors.
Fedyanin M; Tryakin A; Bulanov A; Vybarava A; Tjulandina A; Chekini D; Sekhina O; Figurin K; Garin A; Tjulandin S
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1259-64. PubMed ID: 25586890
[TBL] [Abstract][Full Text] [Related]
6. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
[TBL] [Abstract][Full Text] [Related]
7. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
8. Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
Gholam D; Fizazi K; Terrier-Lacombe MJ; Jan P; Culine S; Theodore C
Cancer; 2003 Aug; 98(4):745-52. PubMed ID: 12910518
[TBL] [Abstract][Full Text] [Related]
9. Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser C; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Aurilio G; Casadei C; Tran B; Dieckmann KP; Brito M; Ruf C; Oing C; Bokemeyer C
Eur J Cancer; 2020 Jun; 132():127-135. PubMed ID: 32361383
[TBL] [Abstract][Full Text] [Related]
10. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
Mencel PJ; Motzer RJ; Mazumdar M; Vlamis V; Bajorin DF; Bosl GJ
J Clin Oncol; 1994 Jan; 12(1):120-6. PubMed ID: 7505805
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.
Garcia-del-Muro X; Maroto P; Gumà J; Sastre J; López Brea M; Arranz JA; Lainez N; Soto de Prado D; Aparicio J; Piulats JM; Pérez X; Germá-Lluch JR
J Clin Oncol; 2008 Nov; 26(33):5416-21. PubMed ID: 18936476
[TBL] [Abstract][Full Text] [Related]
13. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma.
Fosså A; Fosså SD
Br J Urol; 1989 Apr; 63(4):408-15. PubMed ID: 2653557
[TBL] [Abstract][Full Text] [Related]
14. Germ Cell Cancer and Multiple Relapses: Toxicity and Survival.
Lauritsen J; Kier MG; Mortensen MS; Bandak M; Gupta R; Holm NV; Agerbaek M; Daugaard G
J Clin Oncol; 2015 Oct; 33(28):3116-23. PubMed ID: 26240225
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
Yamamoto M; Watanabe K; Fukuda T; Miura O
Anticancer Res; 2017 May; 37(5):2655-2662. PubMed ID: 28476841
[TBL] [Abstract][Full Text] [Related]
16. First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.
Oing C; Lorch A; Bokemeyer C; Honecker F; Beyer J; Berger LA; Oechsle K
J Cancer Res Clin Oncol; 2015 May; 141(5):923-31. PubMed ID: 25395217
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
18. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
19. E400P in advanced seminoma of good prognosis according to the international germ cell cancer collaborative group (IGCCCG) classification: the Spanish Germ Cell Cancer Group experience.
Arranz Arija JA; García del Muro X; Gumà J; Aparicio J; Salazar R; Saenz A; Carles J; Sánchez M; Germà-Lluch JR
Ann Oncol; 2001 Apr; 12(4):487-91. PubMed ID: 11398880
[TBL] [Abstract][Full Text] [Related]
20. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
